On Invalid Date, Acorda Therapeutics (NASDAQ: ACOR) reported Q1 2023 earnings per share (EPS) of -$0.69, up 62.7% year over year. Total Acorda Therapeutics earnings for the quarter were -$16.82 million. In the same quarter last year, Acorda Therapeutics's earnings per share (EPS) was -$1.85.
As of Q2 2023, Acorda Therapeutics's earnings has grown year over year. Acorda Therapeutics's earnings in the past year totalled -$58.22 million.
What is ACOR's earnings date?
Acorda Therapeutics's earnings date is Invalid Date. Add ACOR to your watchlist to be reminded of ACOR's next earnings announcement.
What was ACOR's revenue last quarter?
On Invalid Date, Acorda Therapeutics (NASDAQ: ACOR) reported Q1 2023 revenue of $22.26 million up 1.22% year over year. In the same quarter last year, Acorda Therapeutics's revenue was $22.53 million.
What was ACOR's revenue growth in the past year?
As of Q2 2023, Acorda Therapeutics's revenue has grown -3.63% year over year. This is 73.16 percentage points lower than the US Biotechnology industry revenue growth rate of 69.54%. Acorda Therapeutics's revenue in the past year totalled $118.29 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.